ROZLYTREK is indicated for the treatment of adults with solid tumors that:
• have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
• are metastatic or where surgical resection is likely to result in severe morbidity, and
• have either progressed following treatment or have no satisfactory alternative therapy.
ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.